Abstract
Aspergillus is an opportunistic mold, which is very widespread in the environment. Strains of A. fumigatus, A. Flavus, A. Niger and other Aspergillus species can inhabit different types of environments. Some species, such as Aspergillus fumigatus, can cause a variety of life-threatening allergic reactions and systemic infections in humans, being responsible for more than 90 % of infections. The incidence of aspergillosis cerebral is not known, but has increased markedly in recent years, since it occurs mainly in patients with severe immunodeficiency. In this section a detailed review on Aspergillus, especially A. fumigatus as it is a microorganism little known with a limited spectrum of treatment, but it represents an ominous threat for human health and mortality.
References
Cray JA, Bell ANW, Bhaganna P, Mswaka AY, Timson DJ, Hallsworth JE. The biology of habitat dominance; can microbes behave as weeds? Microb Biotechnol. 2013;6(5):453- 92. doi: 10.1111/1751-7915.12027.
Stevenson A, Cray JA, Williams JP, Santos R, Sahay R, Neuenkirchen N, et al. Is there a common water-activity limit for the three domains of life. ISME J. 2015;9(6):1333-51. doi: 10.1038/ismej.2014.219.
Paulussen C, Hallsworth JE, Alvarez-Pérez S, Nierman WC, Hamill PG, Blain D, et al. Ecology of aspergillosis: insights into the pathogenic potency of Aspergillus fumigatus and some other Aspergillus species. Microb Biotechnol. 2017;10(2):296-322. doi: 10.1111/1751-7915.12367.
Gago S, Denning DW, Bowyer P. Pathophysiological aspects of Aspergillus colonization in disease. Med Mycol. 2019;57:S219-27. doi: 10.1093/mmy/myy076.
Amanati A, Lotfi M, Masoudi MS, Jafarian H, Ghasemi F, Bozorgi H, et al. Cerebral and pulmonary aspergillosis, treatment and diagnostic challenges of mixed breakthrough invasive fungal infections: Case report study. BMC Infect Dis. 2020;20(1):1-7. doi: 10.1186/s12879-020-05162-9.
Vázquez E, Messina F, Santiso G, Metta H, Negroni R. Aspergilosis cerebral como causa de lesión cerebral focal asociada SIDA. A propósito de un caso y revisión de la literatura. Rev Chil Infectol. 2017;34(5):502-6. doi: 10.4067/S0716-10182017000500502.
Shamim MS, Enam SA, Ali R, Anwar S. Craniocerebral aspergillosis: A review of advances in diagnosis and management. J Pak Med Assoc. 2010;60(7):573-9.
Góralska K, Blaszkowska J, Dzikowiec M. Neuroinfections caused by fungi. Infection. 2018;46(4):443-59. doi: 10.1007/s15010-018-1152-2.
Wiesner DL, Klein BS. Lung epithelium: barrier immunity to inhaled fungi and driver of fungal-associated allergic asthma. Curr Opin Microbiol. 2017;40:8-13. doi: 10.1016/j.mib.2017.10.007.
Bertuzzi M, Hayes GE, Icheoku UJ, van Rhijn N, Denning DW Osherov N, et al. Anti-Aspergillus activities of the respiratory epithelium in health and disease. J Fungi. 2018;4(1). doi: 10.3390/jof4010008.
Fortún J, Carratalá J, Gavaldá J, Lizasoain M, Salavert M, De La Cámara R, et al. Guidelines for the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMc). 2011 Update. Enferm Infecc Microbiol Clin. 2011;29(6):435-54. doi: 10.1016/j.eimc.2011.01.010.
Tischler BY, Hohl TM. Menacing mold: Recent advances in Aspergillus pathogenesis and host defense. J Mol Biol. 2019;431(21):4229-46. doi: 10.1016/j.jmb.2019.03.027.
Mathur M, Johnson CE, Sze G. Fungal infections of the central nervous system. Neuroimaging Clin N Am. 2012;22(4):609-32. doi: 10.1016/j.nic.2012.04.004.
Neyaz Z, Singh V, Mehrotra A, Jain M. Cerebral aspergillosis mimicking a neoplasm in an immunocompetent patient. Int J Appl Basic Med Res. 2017;8(4):269-71. doi: 10.4103/ijabmr.IJABMR_393_17.
Fortún J, Meije Y, Fresco G, Moreno S. Aspergilosis. Formas clínicas y tratamiento. Enferm Infecc Microbiol Clin. 2012;30(4):201-8. doi: 10.1016/j.eimc.2011.12.005.
Kulanthaivelu K, Prasad C, Kumar Reddy YV, Mahadevan A. Holohemispheric invasive Aspergillus granulomatous cerebritis of the brain. World Neurosurg. 2020;134:170-5. doi: 10.1016/j.wneu.2019.09.100.
Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):e1-60. doi: 10.1093/cid/ciw326.
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin b for primary therapy of invasive Aspergillosis. N Engl J Med. 2007;347(6):408-15. doi: 10.1056/NEJMoa020191.
Cojutti PG, Merelli M, Allegri L, Damante G, Bassetti M, Pea F. Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring. Br J Clin Pharmacol. 2019;85(1):266-9. doi: 10.1111/bcp.13789.
Schauwvlieghe AFAD, Bredius RGM, Verdijk RM, Smiers FJW, van der Beek MT, Goemans BF, et al. Management of cerebral azole-resistant Aspergillus fumigatus infection: A role for intraventricular liposomal-amphotericin B. J Glob Antimicrob Resist. 2020;22:354-7. doi: 10.1016/j.jgar.2020.03.016.
Zakaria A, Osman M, Dabboussi F, Rafei R, Mallat H, Papon N, et al. Recent trends in the epidemiology, diagnosis, treatment, and mechanisms of resistance in clinical Aspergillus species: A general review with a special focus on the Middle Eastern and North African region. J Infect Public Health. 2020;13(1):1-10. doi: 10.1016/j.jiph.2019.08.007.
Gheith S, Saghrouni F, Bannour W, Youssef Y Ben, Khelif A, Normand AC, et al. In vitro susceptibility to amphotericin b, itraconazole, voriconazole, posaconazole and caspofungin of Aspergillus spp. isolated from patients with haematological malignancies in Tunisia. Springerplus. 2014;3(1):1-8. doi: 10.1186/2193-1801-3-19.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.